You are viewing an incomplete version of our website. Please click to reload the website as full version.

p53 antibody (Tumor Protein P53) (full length)

Details for Product anti-TP53 Antibody No. ABIN967416, Supplier: Log in to see
Antigen
  • bbl
  • BCC7
  • bfy
  • bhy
  • brp53
  • drp53
  • etID22686.5
  • fb40d06
  • LFS1
  • p44
  • P53
  • p53
  • tp53
  • TP53
  • Tp53
  • TpMs
  • Trp53
  • TRP53
  • wu:fb40d06
  • Xp53
  • zgc:111919
Alternatives
anti-Human p53 antibody for Immunohistochemistry (Paraffin-embedded Sections)
Epitope
full length
164
110
89
64
64
63
54
51
51
50
48
46
41
39
31
30
27
26
25
22
22
20
19
17
17
13
13
13
13
13
12
12
9
9
9
9
8
8
8
8
8
7
7
7
7
6
6
6
6
6
6
6
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human, Mouse (Murine), Rat (Rattus)
2048
380
309
124
102
93
56
54
27
23
19
16
13
11
10
10
5
4
4
3
3
2
2
1
Host
Mouse
1241
915
7
4
3
1
1
Clonality (Clone)
Monoclonal ()
Conjugate
This p53 antibody is un-conjugated
66
61
47
44
31
31
23
23
17
17
16
16
16
14
14
14
14
14
13
13
13
13
13
13
13
12
12
4
4
4
4
4
4
4
4
4
3
3
1
1
Application
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Intracellular Staining (ICS), Immunoprecipitation (IP), Western Blotting (WB)
1657
717
558
488
437
427
397
236
196
156
53
39
35
17
16
13
12
11
11
9
8
4
3
3
2
2
2
2
1
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see

Available images

'Independent Validation' Badge
Lot Number 2335876
Method validated Western Blotting
Positive Control U251-MG cells
Negative Control PC3 cells
Notes Strong bands of the expected size were observed in the positive control sample, and not in the negative control sample.
Primary Antibody
  • Antibody: Tumor Protein P53 (TP53) antibody
  • Catalog number: ABIN967416
  • Supplier: Log in to see
  • Supplier catalog number: Log in to see
  • Lot number: 2335876
Secondary Antibody
Controls
  • U251-MG (positive) and PC3 (negative) cell line extracts were prepared using RIPA buffer (R0278, Sigma Aldrich).
  • Loading control: blots were stripped and re-probed for beta-actin to ensure equal loading of lysates.
Protocol
  • 1. Total protein extracts were boiled in 1X SDS Sample Buffer containing 1% SDS and 1.25%
  • Beta-mercaptoethanol at 95°C for 5 min prior to loading.
  • 2. 32 µg of boiled extracts were loaded and resolved on a 8-16% SDS-polyacrylamide gel.
  • 3. The Spectra Multicolor Broad Range molecular mass marker (26634 Thermo Scientific) was used as a
  • standard.
  • 4. Proteins were then transferred onto PVDF membrane by tank transfer and protein transfer was
  • confirmed with Ponceau S staining.
  • 5. The immunoblot membrane was blocked in PBS containing 3% (W/V) non-fat dry milk at room
  • temperature for 1 h.
  • 6. The membrane was rinsed with PBS containing 0.05% Tween-20 once.
  • 7. The membrane was immersed with the protein side up in the antibody solution in PBS containing 1%
  • (W/V) non-fat dry milk and incubated for 2 h at room temperature (~26°C).
  • 8. The membrane was rinsed in PBS containing 0.05% Tween-20 thrice for 10 min each.
  • 9. The membrane was incubated in the HRP-conjugated secondary antibody solution in PBS containing
  • 1% (W/V) non-fat dry milk and incubated for 1 h at room temperature (~26°C) with gentle agitation.
  • 10. The membrane was rinsed thrice PBS containing 0.05% Tween-20 thrice for 10 min each.
  • 11. The membrane was washed in PBS twice for 30 sec each.
  • 12. Signals were detected with Pierce ECL Western Blotting Substrate (32109, Thermo Scientific). The
  • blot was scanned for 300 sec.
  • 13. The membrane was rinsed three times with PBS containing 0.05% Tween-20.4. Incubated in Acidic Glycine Stripping Buffer at room temperature with gentle agitation for 3 times, 10
  • min each.
  • 15. The membrane was washed in PBS containing 0.05% Tween-20 times for 10 min each.
  • 16. Repeated Steps 5-12 with the loading control antibody (beta-actin) and its matching secondary
  • antibody.
Experimental Notes None
Validation Images
Western Blotting validation image for anti-Tumor Protein P53 (TP53) (full length) antibody (ABIN967416) Figure 1: Western blot analysis of U251-MG and PC3 cell line extracts using Tumor Pro...
Brand BD Pharmingen™
Immunogen Recombinant full-length human p53
Clone G59-12
Isotype IgG1
Cross-Reactivity Mouse (Murine), Rat (Rattus)
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Alternative Name p53 (TP53 Antibody Abstract)
Background P53 is a 53 kD nuclear phosphoprotein that acts as a tumor suppressor protein, and is involved in inhibiting cell proliferation when DNA damage occurs. The gene for p53 is the most commonly mutated gene yet identified in human cancers. Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder and several other organs. The mutant p53 is overexpressed in a variety of transformed cells and the wildtype p53 forms specific complexes with several viral oncogenes including SV40 large T, E1B from adenovirus and E6 from human papilloma virus. Wildtype p53 plays a role as a checkpoint protein for DNA damage during the S-phase of the cell cycle. p53 migrates at a reduced molecular weight of 53 kDa. Clone G59-12 recognizes mutant and wild type human, rat and mouse p53 tumor suppressor protein. Recombinant full-length human p53 was used as immunogen.
Molecular Weight 53 kDa
Research Area Cancer, Cell Cycle, Transcription Factors, DNA/RNA, Apoptosis/Necrosis
Pathways p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling
Application Notes Clone G59-12 conjugated to R-Phycoerythrin (PE) is suggested for flow cytometric analysis of p53. Positive control cell lines include SKBR-3 human breast carcinoma cells (ATCC HTB-30) and A431 human vulval carcinoma cells (ATCC CRL-1555). Jurkat T cells (ATCC TIB-152) or MCF-7 human breast carcinoma cells (ATCC HTB-22) are suggested as negative controls. Positive immunostaining is seen in a high proportion of breast and colon carcinomas. p53 staining is not typically detected in normal skin, brain, kidney, lung, stomach, or breast tissue.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store undiluted at 4°C.
Supplier Images
Western Blotting (WB) image for anti-p53 antibody (Tumor Protein P53) (full length) (ABIN967416) Western blot analysis of p53. A SV-40 transformed rat granulosa cell lysate was probe...
 image for anti-p53 antibody (Tumor Protein P53) (full length) (ABIN967416) anti-Tumor Protein P53 (TP53) (full length) antibody (Image 2)
Product cited in: Van Meir, Roemer, Diserens, Kikuchi, Rempel, Haas, Huang, Friedmann, de Tribolet, Cavenee: "Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 4, pp. 1008-12, 1995 (PubMed).

Jacquemier, Molès, Penault-Llorca, Adélaide, Torrente, Viens, Birnbaum, Theillet: "p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results." in: British journal of cancer, Vol. 69, Issue 5, pp. 846-52, 1994 (PubMed).

Mørkve, Halvorsen, Stangeland, Gulsvik, Laerum: "Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer." in: International journal of cancer. Journal international du cancer, Vol. 52, Issue 6, pp. 851-5, 1993 (PubMed).

van den Berg, Baas, Polak, Offerhaus: "Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid." in: The American journal of pathology, Vol. 142, Issue 2, pp. 381-5, 1993 (PubMed).

Yeargin, Cheng, Yu, Gjerset, Bogart, Haas: "P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines." in: The Journal of clinical investigation, Vol. 91, Issue 5, pp. 2111-7, 1993 (PubMed).

Cheng, Yee, Yeargin, Friedmann, Haas: "Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene." in: Cancer research, Vol. 52, Issue 1, pp. 222-6, 1992 (PubMed).

Yeargin, Cheng, Haas: "Role of the p53 tumor suppressor gene in the pathogenesis and in the suppression of acute lymphoblastic T-cell leukemia." in: Leukemia, Vol. 6 Suppl 3, pp. 85S-91S, 1992 (PubMed).

Vogelstein: "Cancer. A deadly inheritance." in: Nature, Vol. 348, Issue 6303, pp. 681-2, 1991 (PubMed).

Background publications Vojt?sek, Bártek, Midgley, Lane: "An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53." in: Journal of immunological methods, Vol. 151, Issue 1-2, pp. 237-44, 1992 (PubMed).

Gjerset, Arya, Volkman, Haas: "Association of induction of a fully tumorigenic phenotype in murine radiation-induced T-lymphoma cells with loss of differentiation antigens, gain of CD44, and alterations in p53 protein levels." in: Molecular carcinogenesis, Vol. 5, Issue 3, pp. 190-8, 1992 (PubMed).

Stein, Stoica, Tilley, Burghardt: "Rat ovarian granulosa cell culture: a model system for the study of cell-cell communication during multistep transformation." in: Cancer research, Vol. 51, Issue 2, pp. 696-706, 1991 (PubMed).